Latest Content

In this week’s health equity news, ICHRAs may offer flexible health coverage options amid ACA subsidy uncertainties, and advocates rally for mental health funding stability.

Richter transformation with CNS involvement in CLL presents a poor prognosis, highlighting the need for tailored treatment strategies and further research.

FDA granted breakthrough therapy designation to pemvidutide based on its potential in treating metabolic dysfunction–associated steatohepatitis (MASH).

Jose Guzman Garcia, PharmD, MHA, BCCCP, discusses key pharmacy initiatives at UC Davis Health.

With ACA subsidies in limbo, ICHRAs may reshape how Americans access coverage. Here are 5 FAQs explaining what they are, who benefits, and key trade-offs.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Teclistamab was approved to treat relapsed/refractory multiple myeloma under the FDA’s accelerated approval pathway in October 2022.

Trump's Great Healthcare Plan aims to lower drug prices, reduce insurance premiums, and enhance transparency, according to the White House.

The Trump administration says it will restore vital SAMHSA funding after swift advocacy from mental health supporters.